Quick Hits: Opioid/Benzodiazepine Warning & More

Can Opioid Painkiller Training for Doctors Stem Abuse?
Can Opioid Painkiller Training for Doctors Stem Abuse?
Last updated:

Quick Hits: “Black box” warnings – the strongest the FDA can mandate – will be added to the labeling of prescription opioid drugs and benzodiazepines amid growing concern about side effects when the medications are taken together. An FDA review found cases where people taking both drug classes experienced serious side effects, including slowed or difficulty breathing, and even death. Both opioids, which are used to treat pain, and benzodiazepines, which are tranquilizers, depress the body’s central nervous system. The agency is also advising health care professionals to limit prescribing of opioids and benzodiazepines together only to patients for whom no other alternatives are available. Posted August 31, 2016. Via FDA.

Quick Hits: The DEA is set to ban kratom, a plant-derived drug currently sold as a dietary supplement, over concerns it is addicting and has no medicinal value. The DEA wants to list kratom as a schedule I drug under the Controlled Substances Act, putting it in the same class as heroin and LSD. Kratom is known for its sedative properties, and has even been used by some as a pain reliever. There have also been anecdotal reports of people using kratom to come off dependence on prescription opioids or heroin. However, in July, the CDC noted that kratom can be abused, and between 2010 and 2015, poison control centers received more than 660 calls related to kratom. Posted August 31, 2016. Via Federal Register.

Quick Hits: The FDA has approved a biosimilar version of the autoimmune disease treatment Enbrel (etanercept). The approval is only the second time the agency has approved a biosimilar – in essence, a generic version – of a biologic based drug, which can costs tens of thousands of dollars per year. Like Enbrel, Erelzi (etanercept-szzs) is indicated to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. Posted August 30, 2016. Via FDA.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Recommend More Articles Like This?

Show Comments (0)
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x